Abstract:Background: Liver transplantation (LT) is a well-established treatment for hepatocellular carcinoma (HCC), but there are ongoing debates regarding outcomes and selection. This study examines the experience of LT for HCC at a high-volume center. Methods: A prospectively maintained database was used to identify HCC patients undergoing LT from 2000-2020 with > 3 years follow-up. Data was obtained from the center database and electronic medical records. The Metroticket 2.0 HCC-specific five-year survival scale was calculated for each patient. Kaplan-Meier and Cox-regression analyses were employed assessing survival between groups based on Metroticket score and individual donor and recipient risk factors. Results: 569 patients met criteria. Median follow-up was 96.2 months (8.12 y; IQR 59.9-147.8). Three-year recurrence-free (RFS) and overall survival (OS) were 88.6% (n=504) and 86.6% (n=493). Five-year RFS and OS were 78.9% (n=449) and 79.1% (n=450). Median Metroticket 2.0 score was 0.9 (IQR 0.9-0.95). Tumor size>3 cm ( P =0.012), increasing tumor number on imaging ( P =0.001) and explant pathology ( P <0.001) was associated with recurrence. Transplant within Milan ( P <0.001) or UCSF-criteria ( P <0.001) had lower recurrence rates. Increasing AFP-values were associated with more HCC-recurrence ( P <0.001) and reduced OS ( P =0.008). Chemoembolization was predictive of recurrence in the overall population ( P =0.043) and in those outside Milan criteria ( P =0.038). A receiver-operator curve using Metroticket 2.0 identified an optimal cut-off of projected survival > 87.5% for predicting recurrence. This cut-off was able to predict RFS ( P <0.001) in the total cohort and predict both, RFS ( P =0.007) and OS ( P =0.016) outside-Milan. Receipt of donation after brain death (DBD) grafts (55/478, 13%) or living-donor grafts (3/22, 13.6%) experienced better survival rates compared to donation after cardiac death (DCD) grafts (n=15/58, 25.6%, P =0.009). Donor age was associated with a higher HCC-recurrence ( P =0.006). Both total ischemia time (TIT)>6hours ( P =0.016) and increasing TIT correlated with higher HCC-recurrence ( P =0.027). The use of DCD-grafts for outside-Milan candidates was associated with increased recurrence ( P =0.039) and reduced survival ( P =0.033). Conclusion: This large two-center analysis confirms favorable outcomes after LT for HCC. Tumor size and number, pre-transplant AFP, and Milan criteria remain important recipient HCC-risk factors. A higher donor risk (i.e., donor age, DCD-grafts, ischemia time) was associated with poorer outcomes.

No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Living Donor Liver Transplantation

Small graft size and hepatocellular carcinoma outcomes in living donor liver transplantation: a retrospective multicentric cohort study

Association of Graft-to-Recipient Weight Ratio with the Prognosis Following Liver Transplantation: a Meta-analysis

Graft Size Alone Should Not Affect Donors Selection and Be Used to Predict the Prognosis of Recipients after Living Donor Liver Transplantation

Smaller Grafts Do Not Imply Early Recurrence in Recipients Transplanted for Hepatocellular Carcinoma: A Chinese Experience

Effects of Graft and Recipient Weight Ratio on the Prognosis after Living-Donor Liver Transplantation for Children with Biliary Atresia

Influence of graft size matching on outcomes of infantile living donor liver transplantation

A retrospective study investigating the risk of graft loss in living donor liver transplant cases where size mismatching is predicted from graft-to-recipient weight ratio

Graft-to-recipient Weight Ratio Exerts Nonlinear Effects on Prognosis by Interacting with Donor Liver Macrosteatosis

Liver Graft-to-Spleen Volume Ratio as a Useful Predictive Factor of the Outcomes in Living Donor Liver Transplantation: A Retrospective Study

Effect of Graft Size Matching on Pediatric Living-Donor Liver Transplantation at a Single Center

Impact of graft/recipient weight ratio on the prognosis of infants with whole liver transplantation

Safety of patients with a graft to body weight ratio less than 0.8% in living donor liver transplantation using right hepatic lobe without middle hepatic vein.

Impact of Non-middle Hepatic Vein Reconstruction on the Result of Low Graft-to-recipient Weight Ratio Living Donor Liver Transplantation

Clinical Outcomes and Risk Factors of Hepatocellular Carcinoma Treated by Liver Transplantation: A Multi-Centre Comparison of Living Donor and Deceased Donor Transplantation

Living Donor Liver Transplantation Does Not Increase Tumor Recurrence of Hepatocellular Carcinoma Compared to Deceased Donor Transplantation.

Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation For Hepatocellular Carcinoma: A Meta-Analysis

Outcome of Hepatocellular Carcinoma Treated by Liver Transplantation: Comparison of Living Donor and Deceased Donor Transplantation.

Prognostic impact of serum soluble PD-1 and ADV score for living donor liver transplantation in patients with previously untreated hepatocellular carcinoma

Hepatic Arterial Buffer Response Maintains the Homeostasis of Graft Hemodynamics in Patient Receiving Living Donor Liver Transplantation

Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-center experience